Taladegib Pulmonary Fibrosis Treatment Patent Granted to Endeavor BioMedicines
Summary
The USPTO granted Patent US12605380B2 to Endeavor BioMedicines, Inc. covering methods of treating pulmonary fibrosis by administering taladegib. The patent, with 29 claims, classifies under CPC codes A61K 31/502 and A61P 11/00. The filing date was September 12, 2025, under Application No. 19327711.
What changed
USPTO granted Patent US12605380B2 covering methods of treating pulmonary fibrosis using taladegib, assigned to Endeavor BioMedicines, Inc. The patent includes 29 claims and is classified under A61K 31/502 and A61P 11/00.
Pharmaceutical companies developing hedgehog pathway inhibitors or competing pulmonary fibrosis treatments should review this patent to assess potential freedom-to-operate implications. Companies licensing or acquiring pulmonary fibrosis therapies should also consider this newly-granted IP position.
Archived snapshot
Apr 21, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Methods of improving lung function
Grant US12605380B2 Kind: B2 Apr 21, 2026
Assignee
Endeavor BioMedicines, Inc.
Inventors
Miguel de los Rios, John Hood, Anita J. DiFrancesco, Luis A Dellamary, Paul A. Frohna
Abstract
The present disclosure provides methods of treating pulmonary fibrosis, the methods comprising administering taladegib to a subject in need thereof.
CPC Classifications
A61K 31/502 A61P 11/00
Filing Date
2025-09-12
Application No.
19327711
Claims
29
Mentioned entities
Parties
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.